These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16985962)

  • 1. Landmark studies impacting the medical management of benign prostatic hyperplasia.
    Lepor H
    Rev Urol; 2003; 5 Suppl 4(Suppl 4):S34-41. PubMed ID: 16985962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Landmark studies impacting the medical management of benign prostatic hyperplasia.
    Lepor H
    Rev Urol; 2003; 5 Suppl 5(Suppl 5):S28-35. PubMed ID: 16985967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of combination therapy in patients with benign prostatic hyperplasia.
    McVary KT
    Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
    Kaplan SA; McConnell JD; Roehrborn CG; Meehan AG; Lee MW; Noble WR; Kusek JW; Nyberg LM;
    J Urol; 2006 Jan; 175(1):217-20; discussion 220-1. PubMed ID: 16406915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
    Liu Q; Zhu Y; Liu J; Qi J; Kang J
    Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia?
    McVary KT; Rogers T; Mahon J; Gupta NK
    J Sex Med; 2018 Dec; 15(12):1728-1738. PubMed ID: 30446471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical therapy for benign prostatic hyperplasia: a review of the literature.
    Clifford GM; Farmer RD
    Eur Urol; 2000 Jul; 38(1):2-19. PubMed ID: 10859436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.
    Smith AB; Carson CC
    Ther Clin Risk Manag; 2009 Jun; 5(3):535-45. PubMed ID: 19707263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
    Tarter TH; Vaughan ED
    Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary.
    Spatafora S; Conti G; Perachino M; Casarico A; Mazzi G; Pappagallo GL;
    Curr Med Res Opin; 2007 Jul; 23(7):1715-32. PubMed ID: 17588302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
    Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
    J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ; Howe RW
    BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
    Doggrell SA
    Expert Opin Pharmacother; 2004 May; 5(5):1209-11. PubMed ID: 15155119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia.
    Kim ED
    Curr Urol Rep; 2004 Aug; 5(4):267-73. PubMed ID: 15260926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
    Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
    BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.